30 results about "Dextran sodium sulfate" patented technology

The invention discloses application of copper-amino acid nano enzyme in preparation of anti-inflammatory drugs, and relates to the technical field of biomedical new materials, amino acids comprise glycine, arginine, histidine, threonine, phenylalanine and cysteine; the ratio of the amino acid to the copper ions is 1: (0.5-5), and the synthesis temperature of the copper-cysteine nano enzyme is 25-125 DEG C. The copper-amino acid nano-enzyme library established by the invention has efficient hydroxyl free radical, superoxide free radical and hydrogen peroxide scavenging activity; wherein the copper-cysteine nano-enzyme shows the highest enzymatic activity, and shows low toxicity and good biocompatibility in both the cell level and the animal level; meanwhile, the copper-cysteine nano-enzyme also shows anti-inflammatory activity and anti-oxidative stress activity, can remarkably improve cell inflammation and body inflammation, relieves and treats dextran sodium sulfate induced mouse ulcerative colitis, and can be further applied to preparation of drugs for treating inflammatory bowel diseases.

The invention discloses a piglet intestinal health targeting probiotic engineering bacterium compound as well as preparation and application thereof. The compound is FP (at) EcN-pnirNKL, wherein a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin, and a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin; b) the recombinant plasmid pnirBMisL-NK-Lysin comprises an NK-Lysin gene optimized by a codon, and the NK-Lysin gene is integrated into the anaerobic inducible plasmid pnirBMisL through homologous recombination; c) the FP is a composite nano-particle which takes nano mesoporous silica (MSN) as a core and is formed by crosslinking fucoidin and rhodiola rosea polysaccharide; and d) the FP (at) EcN-pnirNKL is an oral delivery system which is formed by encapsulating the engineering bacterium EcN-pnirNKL in the FP nano particles. When the compound is applied to prevention and treatment of stress response of weaned piglets, various typical symptoms, including weight loss, colon shortening, histopathological injury and colitis disease response, of the piglets induced by dextran sodium sulfate can be remarkably relieved, and meanwhile, the integrity and functions of an intestinal barrier structure are effectively protected.

The invention relates to the technical field of intestinal inflammation disease prevention and treatment, in particular to a polypeptide for treating ulcerative colitis. The polypeptide provided by the invention is an active heptapeptide derived from natural protein, and has a clear chemical structure and a repeatable preparation process. Research results show that the polypeptide can significantly improve symptoms of mouse ulcerative colitis induced by dextran sodium sulfate (DSS), including weight loss reduction, disease activity index (DAI) reduction, colon length recovery, colon tissue pathological damage improvement and inflammation-related signal pathway inhibition, so that the improvement effect of the polypeptide on intestinal inflammation is verified. The polypeptide is prepared into a pharmaceutical composition or health-care food, so that the comprehensive effects of considering prevention and treatment and simultaneously improving inflammation and repairing barriers can be realized, and a new strategy and a material basis are provided for preventing and treating ulcerative colitis and other intestinal inflammatory diseases.

This invention discloses the application of chestnut total burr ethanol extract in the preparation of anti-colitis drugs. In this invention, the chestnut total burr ethanol extract with anti-colitis properties is obtained by extracting chestnut total burrs with 70% ethanol. This chestnut total burr ethanol extract inhibits the production of LPS-induced pro-inflammatory mediators (NO) and pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) without cytotoxicity; it has a significant inhibitory effect on dextran sulfate sodium-induced colitis in mice, including slowing down weight loss, reducing mouse DAI scores, alleviating colonic tissue damage, downregulating the levels of IL-6, IL-1β, TNF-α, and MDA in mouse colonic tissue and serum, and enhancing the activities of CAT and SOD in mouse colonic tissue and serum. Therefore, the chestnut total burr ethanol extract has significant anti-inflammatory effects both in vivo and in vitro, and can be used to treat colitis.

The invention belongs to the technical field of biomedicine, and particularly relates to application of ME1 in preparation of a medicine for preventing and / or treating inflammatory bowel diseases. The invention discloses an application of an ME1 inhibitor in preparation of drugs for preventing and / or treating inflammatory bowel diseases, and an application of a substance for detecting ME1 in preparation of drugs for diagnosing or detecting inflammatory bowel diseases. The action effect of ME1 * in disease treatment is evaluated through a mouse IBD model induced by dextran sodium sulfate DSS and trinitrobenzene sulfonic acid TNBS, so that a new strategy and method are provided for clinical intervention of IBD. In addition, the invention also clarifies the application of the ME1 as a high-specificity biomarker in IBD diagnosis, and further expands the comprehensive value of the ME1 in disease prevention and treatment.

The present invention relates to a composition for preventing, alleviating or treating fibrosis, the composition comprising bentonite as an active ingredient. Bentonite is highly effective in reducing a disease activity index, inhibiting shortening of colon length, regulating the expression level of a gene related to intestinal fibrosis, reducing a collagen deposition site in intestinal tissue, reducing the expression level of fibronectin and collagen proteins in intestinal tissue in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of ɑ-smooth muscle actin (ɑ-SMA) and collagen proteins in an intestinal fibrosis cell model induced by TGF-β, and is thus expected to be useful as a composition for preventing, alleviating, or treating intestinal fibrosis.

The application discloses curcumin nanoparticles with improved ulcerative colitis efficacy and a preparation method thereof. The application aims to solve the technical bottleneck that curcumin, an anti-inflammatory efficacy component, has poor stability and is difficult to reach the colon site, and provides a preparation method of curcumin nanoparticles with improved ulcerative colitis efficacy based on alkaline pH-mediated assembly and with colon-targeted delivery effect. The nanoparticles are all prepared from food raw materials, and the preparation process is simple, mild, controllable and easy to industrialize, does not involve any organic solvents and chemical reagents, and realizes efficient embedding of curcumin (the embedding rate is as high as 91.4%). The curcumin nanoparticles provided by the application can effectively alleviate the symptoms of dextran sodium sulfate-induced ulcerative colitis in mice in a dose-dependent manner, including improving body weight loss and colon shortening, and significantly inhibiting the expression of pro-inflammatory factors, and the effect is better than that of a conventional positive drug (mesalamine).

This invention discloses the application of psoralen in the preparation of FFA4 receptor agonists and drugs for FFA4 receptor-related diseases. Cellular experiments show that this compound is a concentration-dependent FFA4 agonist; animal experiments show that this compound has significant efficacy in a DSS-induced colitis model, reducing DSS-induced colonic shortening, improving weight loss, and alleviating splenic swelling. This compound can be used in the preparation of FFA4 agonists and in the prevention and treatment of FFA4-related diseases such as inflammatory bowel disease.

This invention, entitled "A Composition Containing Pentadecanoic Acid, Parabacterium Species Outer Membrane Vesicles Containing the Composition, and Their Applications," belongs to the field of probiotics and microbial preparations technology. The technical problem this invention aims to solve is that beneficial live bacteria have weak colonization ability in the gut, are easily affected by the gastrointestinal environment, exhibit unstable individual responses, and struggle to simultaneously address immune regulation and barrier repair. This invention provides a composition containing pentadecanoic acid, Parabacterium Species-derived outer membrane vesicles, and their applications. The outer membrane vesicles are derived from *Parabacterium difficile* and are rich in pentadecanoic acid, palmitic acid, and octadecanoic acid. The composition and outer membrane vesicles prepared by this invention can significantly inhibit macrophage M1 polarization and reduce pro-inflammatory cytokines. TNF-α , IL-6 and IL-1 β It can lower the expression level of [something], reduce intracellular reactive oxygen species levels, improve mitochondrial function, significantly alleviate symptoms of colitis induced by sodium dextran sulfate, regulate the intestinal flora structure, and increase the abundance of beneficial bacteria.

The invention relates to a probiotic composition and application thereof, and belongs to the technical field of compositions. Comprising Ackerman muciniphila ATCC BAA-835 and Bifidobacterium animalis subsp. Lactis BB-12, wherein the CFU (colony forming unit) ratio of the Ackerman muciniphila ATCC BAA-835 to the Bifidobacterium animalis subsp. Lactis BB-12 is 1 The two strains have a synergistic effect, and the prepared probiotic composition can synergistically relieve the phenomena of weight loss, colon shortening, intestinal structure and intestinal barrier injury, proinflammatory factor increase, anti-inflammatory factor reduction, intestinal flora and histidine metabolism disorder and the like of dextran sodium sulfate induced mouse ulcerative colitis. Therefore, the effect of preventing and relieving the severity of the inflammatory bowel disease is achieved.

The invention provides application of barley pest larva defatted protein powder in preparation of drugs for treating inflammatory bowel diseases. The invention belongs to the technical field of medicine, and by establishing a dextran sodium sulfate induced mouse IBD model and lavaging barley pest larva defatted protein powder, it is found that the traditional Chinese medicine composition can relieve IBD mouse colitis symptoms, restore colon length, relieve mucosal lesion, retain goblet cell and crypt structures, reduce inflammatory cell infiltration and down-regulate inflammatory cytokine expression; the compound is expected to play an important role in preparing medicines for treating inflammatory enteritis.

The application discloses a method for preparing high-value cellobiose from a medicine and food homologous Radix Millettiae and application of the high-value cellobiose. The method comprises the following steps: extracting cellulose from Radix Millettiae; optimizing a beta-glucanase enzymolysis process by using a response surface method; after the enzymolysis liquid is subjected to selective removal of glucose through yeast fermentation, the high-value cellobiose product is obtained through acetone precipitation and freeze-drying. The process condition is mild and environment-friendly, high-value utilization of agricultural waste is realized, the obtained cellobiose product has high purity, and an economic and effective approach is provided for large-scale production of cellobiose. Animal experiments prove that the cellobiose product has a significant relieving effect on colonitis induced by dextran sulfate sodium in mice, can effectively improve disease symptoms, reduce oxidative stress, repair intestinal barrier and regulate inflammatory response, and has a good application prospect in preparation of functional food or medicine for relieving colonitis and high-value utilization of Radix Millettiae.

The application provides application of Elaeagnus conferta polysaccharide in preparation of a medicine for treating intestinal barrier related diseases, and relates to the technical field of natural medicine chemistry. The intestinal protection effect of the Elaeagnus conferta polysaccharide on a dextran sodium sulfate induced intestinal injury model of mice is investigated, and the research result shows that the Elaeagnus conferta polysaccharide can treat clinical symptoms such as diarrhea, enteritis and weight loss caused by intestinal barrier injury, significantly reduces disease scores, inhibits colonic tissue goblet cell necrosis, promotes secretion of mucin, increases expression of tight junction proteins, and enhances intestinal mucosal barrier function. As a widely planted fruit and a fruit loved by the public, the Elaeagnus conferta has the advantages of high safety and easy acquisition. It is expected to become an effective active ingredient source for resisting intestinal injury diseases, and has a broad market development prospect.

This invention provides the application of *Pleurotus oosporum* polysaccharide in the preparation of drugs and health foods that regulate intestinal barrier function or protect against intestinal damage-related diseases. Its protective effect against a mouse model of intestinal damage induced by sodium dextran sulfate was investigated. Results showed that *Pleurotus oosporum* polysaccharide significantly improved symptoms such as weight loss, loose stools, and colonic atrophy caused by intestinal damage in mice, reduced the disease activity index, inhibited colonic epithelial destruction, inflammatory cell infiltration, and goblet cell necrosis, and enhanced intestinal mucosal barrier function. As a fungus, *Pleurotus oosporum* has high safety and is a potential source of active ingredients against intestinal damage, showing promising development prospects in intestinal barrier protection.

The application provides use of an S1PR1 biased agonist in preparation of a drug for treating inflammatory bowel disease. The application proves through animal tests that, compared with a dextran sodium sulfate treated inflammatory bowel disease model group of mice, the colon length of mice added with SAR247799 treatment tends to be normalized, and finally the purpose of treating inflammatory bowel disease is achieved, and the application has a practical popularization and application prospect.

The application relates to the technical field of animal model construction, and particularly discloses a Sypl1 gene knockout colorectal cancer mouse model construction method and application, which comprises the following steps: synthesizing a specific target site gRNA of a Sypl1 gene, mixing Cas9 protein and the target site gRNA to obtain an injection compound, microinjecting the injection compound into mouse zygotes, and transplanting the surviving zygotes into the oviducts of pseudopregnant female mice to obtain F0 generation mice, and the mice born after 20 days are Sypl1 gene knockout mouse animal models; and a chemical induction modeling method is used to construct a colorectal cancer model in wild type mice and gene knockout mice. The Sypl1 gene knockout mouse is constructed by using a CRISPR / Cas mediated genome engineering technology Sypl1 combined with the most widely used colorectal cancer chemical inducer azoxymethane / dextran sodium sulfate, a new colorectal cancer mouse model is constructed, compared with a traditional chemical induction model, the tumor formation rate can be significantly improved, and the tumor formation time can be shortened, and a more efficient animal model is provided for colorectal cancer research.

The application discloses application of guaiacol in preparation of a drug for treating ulcerative colitis. Cell experiment results show that the guaiacol can enhance the ability of macrophages to remove apoptotic cells; animal experiment results show that the guaiacol can significantly relieve the disease of a dextran sodium sulfate (DSS)-induced ulcerative colitis mouse, and the specific performance is that the guaiacol can slow down the weight loss degree of the colitis mouse, effectively reduce the disease activity index (DAI) of the colitis mouse, significantly inhibit the shortening of the colon of the colitis mouse, the infiltration of inflammatory cells and the mucosal damage, obviously reduce the level of a pro-inflammatory factor in serum of the mouse, and increase the level of a pro-inflammatory repair factor. In conclusion, the guaiacol has definite curative effect on ulcerative colitis, has no obvious side effect, and has a good prospect of being developed into a drug for treating ulcerative colitis.

The invention relates to the technical field of animal model construction, and particularly discloses a construction method and application of a Sypl1 gene knockout colorectal cancer mouse model, and the construction method comprises the following steps: synthesizing a specific target site gRNA of a Sypl1 gene, uniformly mixing Cas9 protein and the target site gRNA to obtain an injection compound, microinjecting the injection compound into a mouse fertilized egg to obtain a Sypl1 gene knockout colorectal cancer mouse model. And transplanting the survival fertilized ova into the salpingtube of a pseudopregnant female mouse for 20 days to obtain a mouse which is an F0-generation mouse, obtaining a Sypl1 gene knockout mouse animal model, and constructing a colorectal cancer model in a wild type mouse and a gene knockout mouse by adopting a chemical induction modeling method. A Sypl1 gene knockout mouse is constructed through a CRISPR / Cas mediated genome engineering technology, a novel colorectal cancer mouse model is constructed in combination with a colorectal cancer chemical inducer azomethane / dextran sodium sulfate which is most widely applied at present, and compared with a traditional chemical induction model, the novel colorectal cancer mouse model has the advantages that the tumor formation rate can be remarkably increased, the tumor formation time can be shortened, and the tumor formation cost can be reduced. And a more efficient animal model is provided for colorectal cancer research.

This invention discloses the application of psoralen chalcone in the preparation of FFA4 receptor agonists and drugs for FFA4 receptor-related diseases. Cellular experiments show that this compound is a concentration-dependent FFA4 agonist; animal experiments show that this compound has significant efficacy in a DSS-induced colitis model, reducing DSS-induced colonic shortening, improving weight loss, and alleviating splenic swelling. This compound can be used in the preparation of FFA4 agonists and in the prevention and treatment of FFA4-related diseases such as inflammatory bowel disease, non-alcoholic fatty liver disease, and osteoporosis.

The present invention relates to a composition for preventing, alleviating, or treating depression or anxiety disorder, the composition comprising a zeolite as an active ingredient, wherein the zeolite is excellent in increasing activity by alleviating depression or anxiety disorder in open-field tests and light-dark tests using a colitis animal model induced by dextran sulfate sodium salt (DSS), and is thus expected to be useful as a composition for preventing, alleviating, or treating depression or anxiety disorder.

The invention relates to the technical field of biological medicines, in particular to application of garlic polysaccharide in preparation of a medicine for preventing and / or inflammatory colonoma. The invention provides an application of garlic polysaccharide in preparation of a medicine for preventing and / or inflammatory colon tumor, the garlic polysaccharide is mainly formed by connecting fructose and glucose through a beta-configuration glucosidic bond, and the garlic polysaccharide can resist gastrointestinal tract enzyme in digestion simulation to be utilized by intestinal flora glycolysis, so that the total sugar content is continuously reduced. The anti-tumor activity of the garlic polysaccharide is proved by constructing an azomethane (AOM) / dextran sodium sulfate (DSS) induced inflammatory coloma mouse model; meanwhile, a basis is provided for research and development of garlic polysaccharide medicines for preventing and / or treating inflammatory colonoma.

The invention discloses a preparation method and application of elaeagnus angustifolia gum water-soluble homogeneous polysaccharide. According to the method, elaeagnus angustifolia gum is taken as a raw material, and the elaeagnus angustifolia gum water-soluble homogeneous polysaccharide is prepared through extraction, ethanol precipitation, separation and purification. Experiments show that the elaeagnus angustifolia gum water-soluble homogeneous polysaccharide reduces disease activity indexes and improves clinical symptoms by restoring body weight and excrement viscosity and reducing intestinal bleeding; the intestinal tract damaged by inflammation is relieved by repairing the mucosal barrier function of the colon tissue; by inhibiting mucosal lesion and remodeling an intestinal flora structure, dysbacteriosis induced by dextran sodium sulfate is reversed, and overall structure damage, mucosal lesion and colon tissue inflammation infiltration of DSS mice are effectively relieved. The application potential of the elaeagnus angustifolia gum water-soluble homogeneous polysaccharide in treatment of ulcerative colitis is disclosed, and the elaeagnus angustifolia gum water-soluble homogeneous polysaccharide is successfully endowed to the field of modern medicine from traditional application. Experimental research not only verifies the effectiveness of the compound, but also provides a new strategy and direct evidence for developing a novel and safe ulcerative colitis therapy derived from natural products, and has a clear application prospect.

The present invention relates to a composition for preventing, alleviating, or treating inflammatory bowel disease, the composition comprising a Cynomorium songaricum extract as an active ingredient. In an animal model of inflammatory bowel disease induced by dextran sulfate sodium (DSS), the Cynomorium songaricum extract increases body weight reduced due to DSS and reduces increased colon weight, and in particular, a mixture of the Cynomorium songaricum extract and a Gleditsia sinensis sting extract more significantly reduces a disease activity index increased by DSS administration than the Cynomorium songaricum extract or the Gleditsia sinensis sting extract alone. Thus, the composition can be highly effectively used in health functional foods or medicines for preventing, alleviating, or treating inflammatory bowel disease.

The application relates to the technical field of ulcerative colitis prevention and treatment, and particularly relates to application of avicularin in preparation of ulcerative colitis prevention and treatment drugs. Avicularin can effectively improve ulcerative colitis of mice caused by dextran sulfate sodium (DSS), can not only improve colon injury and reduce DAI index, but also can reduce expression of inflammatory cytokines and increase expression of intestinal mucosal barrier related proteins.

The application belongs to the field of biological medicine and microecological intervention technology, and relates to application of Bacillus coagulans T-21 in reducing ulcerative colitis combined with cognitive dysfunction. A dextran sodium sulfate (DSS) induced mouse ulcerative colitis combined with cognitive dysfunction model is established by taking a Bacillus coagulans T-21 strain as an active ingredient, and an intervention effect is evaluated. Results show that the Bacillus coagulans T-21 intervention can improve the cognitive related behavior performance and learning and memory ability of the model mice, thereby reducing ulcerative colitis related cognitive dysfunction. Meanwhile, the Bacillus coagulans T-21 intervention can increase the colon length, up-regulate the expression of tight junction proteins Occludin, Claudin-1 and Claudin-5 in colon tissue, improve the intestinal mucosal barrier damage, and down-regulate the expression levels of pro-inflammatory factors IL-1beta in colon tissue and IL-6 in hippocampus tissue, thereby reducing intestinal and central inflammatory reactions.

The invention relates to application of licraside and a pharmaceutical composition for preventing or treating intestinal epithelial cell injury, and relates to the field of drug development. The licraside is used for preparing a medicine for preventing or treating intestinal epithelial cell injury. The Licraside disclosed by the invention can be used for repairing intestinal epithelial cell injury and has a protective effect on a dextran sodium sulfate induced cell inflammation model; the blank of existing licraside research is filled, and an experimental basis is provided for further development of new drugs.

The present application relates to the technical field of prevention and treatment of intestinal inflammatory diseases, and in particular to a polypeptide for treating ulcerative colitis. The polypeptide provided by the present application is an active heptapeptide derived from a natural protein, has a clear chemical structure and a reproducible preparation process. Research results show that the polypeptide can significantly improve the symptoms of ulcerative colitis induced by dextran sodium sulfate (DSS) in mice, including reducing body weight loss, reducing disease activity index (DAI), restoring colon length, improving colon tissue pathological damage and inhibiting inflammation-related signaling pathways, thereby verifying its improvement effect on intestinal inflammation. By preparing the polypeptide into a pharmaceutical composition, a comprehensive effect of prevention and treatment, inflammation improvement and barrier repair in parallel can be achieved, thereby providing a new strategy and material basis for the prevention and treatment of ulcerative colitis and other intestinal inflammatory diseases.

This invention belongs to the fields of marine product functional applications, functional foods, and biotechnology. It discloses an oyster oligopeptide for alleviating DSS-induced ulcerative colitis, its preparation method, and its uses. Using a DSS-induced damage model of normal human colonic epithelial cells as a guide, oyster meat was enzymatically hydrolyzed, defatted, and precipitated with alcohol to obtain purified oyster hydrolysate. Two oyster peptides were identified, screened using bioinformatics, and verified for synthesis. Their amino acid sequences are shown in SEQ ID NO. 1-2. The oyster oligopeptides exhibit strong antioxidant and anti-inflammatory activities, effectively alleviating DSS-induced NCM460 cell damage, with better effects than the positive control 5-aminosalicylic acid. They can be used to prepare drugs for alleviating ulcerative colitis, as well as foods and health products for adjuvant treatment of ulcerative colitis.

The present invention relates to a composition for preventing, alleviating, or treating intestinal fibrosis, the composition comprising zeolite as an active ingredient. The zeolite according to the present invention is highly effective in reducing the thickness of intestinal tissue and the accumulation of collagen in intestinal tissue and reducing the expression level of a gene related to fibrosis in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of an ɑ-smooth muscle actin (ɑ-SMA) protein in an intestinal fibrosis cell model induced by TGF-β.

The invention discloses application of gastrodin in preparation of a medicine for improving acute enteritis complicated with cognitive impairment. According to the application disclosed by the invention, a mouse model with acute enteritis and cognitive impairment is constructed through induction of dextran sodium sulfate (DSS), and after gastrodin intervention is performed in an intragastric administration manner, remarkable improvement effects are achieved on the aspects of behavioristics, intestinal pathology, intestinal barriers, inflammation regulation, intestinal microecology, metabonomics, proteomics and the like. The gastrodin is used as a single active component, plays a role through a synergistic regulation network of intestinal microecology-intestinal barrier-inflammation regulation-intestinal tract-cerebral axis-central nervous function, realizes double effects of acute enteritis pathological repair and depression-like behavior improvement, has a remarkable improvement effect, and is a novel pharmaceutical composition for treating acute enteritis. The compound is clear in action mechanism, controllable in dosage and good in biocompatibility, brand new active substances and application schemes are provided for intervention of acute enteritis and cognitive impairment, and the compound can be used for preparing related drugs.